Please assess the completion status of the following clinical trial:

Trial Title: Effect of Neutrophil Elastase Inhibitor on Lung Injury After Esophagectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Thoracic esophageal squamous cell carcinoma~Exclusion Criteria:~* Preoperative chemoradiotherapy~* Cardiovascular disease with NYHA grade III or IV~* Pulmonary disorder with Hugh-Jones classification II, III, IV, or V, preo~* Liver cirrhosis~* Renal failure

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): Patients in the control group received saline for 7 days starting at the beginning of surgery
- S group (Type: ACTIVE_COMPARATOR): Patients in the S group received sivelestat sodium hydrate at a dosage 4.8mg/kg/day for 7 days starting at the beginning of surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).